MedTrace Logo

Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients

NCT01588106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2017-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate if the use of the CONTOUR Next USB BGMS system with AutoLog and Trends features and integrated data management software (Glucofacts ™ DELUXE) enables behavioral changes that may lead to improvement in glycemic control, expressed as a reduction in HbA1c as primary endpoint.

Patients will be randomized either to using CONTOUR Next USB or CONTOUR. Patients will be trained in using the devices and return every 3 months until month 9 after baseline.

Conditions

  • Diabetes Mellitus Type 2

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Peter Schwarz, Prof · Universitätsklinikum Carl Gustav Carus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-10-31
Completion
2016-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01588106 on ClinicalTrials.gov